Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
JCO Precision Oncology|September 11, 2020
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent AlterationsYuri Sheikine, Dean Pavlick, Samuel J Klempner, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature Genetics|July 4, 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerZhenfeng Zhang, Jae Cheol Lee, Luping Lin, et al.
The Journal of Molecular Diagnostics : JMD|June 25, 2018
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNATravis A Clark, Jon H Chung, Mark Kennedy, et al.
Blood Cancer Journal|June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assayAndrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
The Oncologist|June 2, 2016
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSiraj M Ali, Thomas Hensing, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2016
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast CancerHeather A Parsons, Julia A Beaver, Ashley Cimino-Mathews, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Pageof 29